)
Visual
earnings real time
GT Biopharma
GT Biopharma (GTBP) investor relations material
GT Biopharma Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary21 Jan, 2026
Company overview and business model
Clinical-stage biopharmaceutical company developing immuno-oncology products using proprietary TriKE® and Dual Targeting TriKE® fusion protein platforms to harness and enhance natural killer (NK) cell cancer-killing abilities.
TriKE®s are designed to target various tumor antigens in hematologic malignancies and solid tumors, with potential for use as monotherapy or in combination with standard therapies.
Platform is scalable, with processes to rapidly produce investigational new drug-ready candidates for internal development or partnerships.
Exclusive rights to the TriKE® platform, with ongoing generation of additional intellectual property.
Financial performance and metrics
As of January 12, 2026, 26,652,194 shares of common stock outstanding, with warrants for up to 50,166,927 additional shares and options for 597,550 shares.
Gross proceeds from the exercise of Greenshoe Rights in 2025 totaled $7.55 million before expenses.
Substantial doubt exists about the ability to continue as a going concern; additional financing is required to fund operations through the next year.
Independent auditor raised substantial doubt about the company’s ability to continue as a going concern in the 2024 financial statements.
Use of proceeds and capital allocation
No proceeds will be received from the sale of shares by selling stockholders; proceeds from any cash exercise of outstanding Vesting Warrants will be used for working capital and general corporate purposes.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- NAZARA
Q1 FY25 saw strong revenue, PAT growth, and major acquisitions fueling future expansion. - SNP
Q4 2025 clean CCS operating result rose 41%, but E&P impairments led to a net loss. - GEHC
Strong 2025 results, record backlog, and margin expansion set up robust 2026 growth. - 4503
Revenue and profit surged on strategic brands, cost savings, and raised full-year forecasts. - BDN
2026 targets FFO growth, higher occupancy, asset sales, and further deleveraging. - ENT
2025 saw $2.8B revenue, $220M EBITDA, $270M cash to parents; 2026 outlook: $3.1–$3.2B revenue. - KREF
Net loss for 2025, but strong liquidity, portfolio repositioning, and active capital management. - ORN
Acquisition expands marine construction scale, capabilities, and long-term growth prospects. - RSVR
Q3 revenue up 8% year-over-year; guidance raised on strong publishing and M&A activity. - IEX
Record HST orders and margin gains support 2026 growth outlook amid macro uncertainties.
Next GT Biopharma earnings date
Q4 202513 Mar, 2026
GT Biopharma
Next GT Biopharma earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
GT Biopharma Inc. is a biotechnology company focused on developing immuno-oncology therapies for cancer treatment. The company specializes in TriKE (Tri-specific Killer Engager) technology, which is designed to enhance the ability of natural killer (NK) cells to target and destroy cancer cells. GT Biopharma’s pipeline includes investigational treatments for hematologic malignancies and solid tumors. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage